| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
|
N Engl J Med
|
2013
|
16.33
|
|
2
|
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.
|
J Clin Oncol
|
2011
|
5.14
|
|
3
|
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
|
N Engl J Med
|
2015
|
5.08
|
|
4
|
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
|
Blood
|
2011
|
5.06
|
|
5
|
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.
|
Blood
|
2008
|
4.61
|
|
6
|
The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.
|
Blood
|
2011
|
3.87
|
|
7
|
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.
|
Blood
|
2006
|
3.48
|
|
8
|
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.
|
Blood
|
2007
|
3.29
|
|
9
|
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
|
Blood
|
2007
|
3.27
|
|
10
|
High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation.
|
Blood
|
2008
|
3.19
|
|
11
|
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.
|
Blood
|
2007
|
3.14
|
|
12
|
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
|
Cancer
|
2006
|
2.77
|
|
13
|
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia.
|
Blood
|
2008
|
2.72
|
|
14
|
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
|
N Engl J Med
|
2015
|
2.66
|
|
15
|
B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.
|
Blood
|
2009
|
2.66
|
|
16
|
Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance.
|
Blood
|
2009
|
2.50
|
|
17
|
NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.
|
J Natl Compr Canc Netw
|
2010
|
2.45
|
|
18
|
Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.
|
Blood
|
2011
|
2.34
|
|
19
|
The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy.
|
Leuk Lymphoma
|
2007
|
2.21
|
|
20
|
Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia.
|
Blood
|
2011
|
2.09
|
|
21
|
Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins.
|
Blood
|
2004
|
2.01
|
|
22
|
Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma.
|
J Clin Oncol
|
2008
|
1.99
|
|
23
|
Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia.
|
Blood
|
2014
|
1.95
|
|
24
|
Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis.
|
Cancer
|
2003
|
1.90
|
|
25
|
Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia.
|
Blood
|
2013
|
1.87
|
|
26
|
Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism.
|
Blood
|
2008
|
1.86
|
|
27
|
CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia.
|
Blood
|
2010
|
1.82
|
|
28
|
AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance.
|
Blood
|
2008
|
1.80
|
|
29
|
CXCR4 is a prognostic marker in acute myelogenous leukemia.
|
Blood
|
2006
|
1.79
|
|
30
|
Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors.
|
Br J Haematol
|
2007
|
1.76
|
|
31
|
Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.
|
Blood
|
2011
|
1.75
|
|
32
|
Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
|
Cancer
|
2004
|
1.75
|
|
33
|
De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience.
|
Blood
|
2009
|
1.75
|
|
34
|
The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization.
|
Blood
|
2013
|
1.63
|
|
35
|
Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells.
|
Blood
|
2009
|
1.62
|
|
36
|
Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach.
|
Blood
|
2009
|
1.58
|
|
37
|
Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia.
|
Blood
|
2007
|
1.56
|
|
38
|
Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens.
|
Blood
|
2008
|
1.46
|
|
39
|
Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.
|
Blood
|
2008
|
1.44
|
|
40
|
Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.
|
Blood
|
2009
|
1.42
|
|
41
|
Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia.
|
J Clin Oncol
|
2012
|
1.38
|
|
42
|
Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact.
|
Epigenetics
|
2010
|
1.37
|
|
43
|
Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia.
|
Cancer
|
2009
|
1.36
|
|
44
|
Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells.
|
Blood
|
2008
|
1.36
|
|
45
|
Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
|
J Clin Oncol
|
2008
|
1.34
|
|
46
|
Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma.
|
J Clin Oncol
|
2010
|
1.33
|
|
47
|
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.
|
Blood
|
2009
|
1.29
|
|
48
|
High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemia.
|
Blood
|
2003
|
1.28
|
|
49
|
Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection.
|
Blood
|
2008
|
1.27
|
|
50
|
Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia.
|
Cancer
|
2003
|
1.26
|
|
51
|
Non-Hodgkin's lymphomas, version 1.2013.
|
J Natl Compr Canc Netw
|
2013
|
1.20
|
|
52
|
Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
|
Mod Pathol
|
2011
|
1.19
|
|
53
|
Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia.
|
Cancer
|
2011
|
1.19
|
|
54
|
Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
|
Cancer
|
2004
|
1.18
|
|
55
|
Non-Hodgkin's lymphomas, version 4.2014.
|
J Natl Compr Canc Netw
|
2014
|
1.17
|
|
56
|
The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients.
|
Clin Cancer Res
|
2008
|
1.16
|
|
57
|
Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center.
|
J Clin Oncol
|
2007
|
1.15
|
|
58
|
Eradication of minimal residual disease in hairy cell leukemia.
|
Blood
|
2006
|
1.13
|
|
59
|
Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia.
|
Blood
|
2010
|
1.12
|
|
60
|
Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells.
|
Blood
|
2009
|
1.12
|
|
61
|
Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.
|
Blood
|
2011
|
1.09
|
|
62
|
Analysis of human leukaemias and lymphomas using extensive immunophenotypes from an antibody microarray.
|
Br J Haematol
|
2006
|
1.07
|
|
63
|
Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia.
|
Blood
|
2011
|
1.07
|
|
64
|
Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP.
|
Blood
|
2005
|
1.06
|
|
65
|
Non-Hodgkin's lymphomas.
|
J Natl Compr Canc Netw
|
2011
|
1.06
|
|
66
|
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.
|
Blood
|
2005
|
1.06
|
|
67
|
Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells.
|
Mol Cancer
|
2013
|
1.04
|
|
68
|
A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine).
|
Blood
|
2005
|
1.03
|
|
69
|
Non-Hodgkin's Lymphomas, version 3.2012.
|
J Natl Compr Canc Netw
|
2012
|
1.03
|
|
70
|
Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients.
|
Br J Haematol
|
2008
|
1.03
|
|
71
|
Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells.
|
Blood
|
2010
|
1.02
|
|
72
|
Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone.
|
Cancer
|
2006
|
0.97
|
|
73
|
Customized oligonucleotide array-based comparative genomic hybridization as a clinical assay for genomic profiling of chronic lymphocytic leukemia.
|
J Mol Diagn
|
2008
|
0.97
|
|
74
|
Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia.
|
Blood
|
2013
|
0.96
|
|
75
|
Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome.
|
Clin Lymphoma Myeloma Leuk
|
2013
|
0.94
|
|
76
|
Non-Hodgkin's lymphomas, version 2.2014.
|
J Natl Compr Canc Netw
|
2014
|
0.94
|
|
77
|
Richter's transformation in chronic lymphocytic leukemia.
|
Curr Hematol Malig Rep
|
2007
|
0.94
|
|
78
|
Chronic lymphocytic leukemia: treatment options for patients with refractory disease.
|
Cancer
|
2009
|
0.93
|
|
79
|
What is the best frontline therapy for patients with CLL and 17p deletion?
|
Curr Hematol Malig Rep
|
2011
|
0.93
|
|
80
|
Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3.
|
Blood
|
2007
|
0.93
|
|
81
|
Identification and validation of biomarkers of IgV(H) mutation status in chronic lymphocytic leukemia using microfluidics quantitative real-time polymerase chain reaction technology.
|
J Mol Diagn
|
2007
|
0.92
|
|
82
|
High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic leukemia.
|
Am J Clin Pathol
|
2010
|
0.92
|
|
83
|
Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia.
|
Cancer
|
2004
|
0.91
|
|
84
|
Clinical characteristics, response to therapy, and survival of African American patients diagnosed with chronic lymphocytic leukemia: joint experience of the MD Anderson Cancer Center and Duke University Medical Center.
|
Cancer
|
2013
|
0.91
|
|
85
|
Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression.
|
Mod Pathol
|
2010
|
0.90
|
|
86
|
Diffuse Large B-Cell Lymphoma Version 1.2016.
|
J Natl Compr Canc Netw
|
2016
|
0.89
|
|
87
|
Mechanisms of cell death of chronic lymphocytic leukemia lymphocytes by RNA-directed agent, 8-NH2-adenosine.
|
Clin Cancer Res
|
2005
|
0.88
|
|
88
|
The great imitator: systemic nocardiosis mimicking Richter's transformation in relapsed chronic lymphocytic leukemia.
|
J Clin Oncol
|
2010
|
0.88
|
|
89
|
Statin and aspirin use is associated with improved outcome of FCR therapy in relapsed/refractory chronic lymphocytic leukemia.
|
Blood
|
2014
|
0.87
|
|
90
|
Impact of bone marrow stromal cells on Bcl-2 family members in chronic lymphocytic leukemia.
|
Leuk Lymphoma
|
2013
|
0.85
|
|
91
|
Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.
|
Eur J Haematol
|
2007
|
0.84
|
|
92
|
LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients.
|
Blood
|
2011
|
0.83
|
|
93
|
Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis.
|
J Clin Pharmacol
|
2014
|
0.82
|
|
94
|
In vivo activation of signal transducer and activator of transcription 1 after CD154 gene therapy for chronic lymphocytic leukemia is associated with clinical and immunologic response.
|
Clin Cancer Res
|
2003
|
0.82
|
|
95
|
Central nervous system relapse in two patients with chronic myelogenous leukemia in myeloid blastic phase on imatinib mesylate therapy.
|
Leuk Lymphoma
|
2004
|
0.81
|
|
96
|
Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.
|
J Natl Compr Canc Netw
|
2015
|
0.81
|
|
97
|
Genomic variation by whole-genome SNP mapping arrays predicts time-to-event outcome in patients with chronic lymphocytic leukemia: a comparison of CLL and HapMap genotypes.
|
J Mol Diagn
|
2012
|
0.80
|
|
98
|
Bone marrow purging studies in acute myelogenous leukemia using the recombinant anti-CD33 immunotoxin HuM195/rGel.
|
Biol Blood Marrow Transplant
|
2003
|
0.80
|
|
99
|
A two-gene signature, SKI and SLAMF1, predicts time-to-treatment in previously untreated patients with chronic lymphocytic leukemia.
|
PLoS One
|
2011
|
0.79
|
|
100
|
Impaired bactericidal but not fungicidal activity of polymorphonuclear neutrophils in patients with chronic lymphocytic leukemia.
|
Leuk Lymphoma
|
2013
|
0.78
|
|
101
|
Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome.
|
Cancer
|
2004
|
0.78
|
|
102
|
Making advances in first-line chronic lymphocytic leukemia treatment.
|
J Clin Oncol
|
2012
|
0.78
|
|
103
|
Ibrutinib: a paradigm shift in management of CLL.
|
Expert Rev Hematol
|
2014
|
0.77
|
|
104
|
Generation of functional CLL-specific cord blood CTL using CD40-ligated CLL APC.
|
PLoS One
|
2012
|
0.77
|
|
105
|
Multiple-dose granulocyte-macrophage-colony-stimulating factor plus 23-valent polysaccharide pneumococcal vaccine in patients with chronic lymphocytic leukemia: a prospective, randomized trial of safety and immunogenicity.
|
Cancer
|
2008
|
0.77
|
|
106
|
A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia.
|
Leuk Lymphoma
|
2014
|
0.76
|
|
107
|
Role of CD20 monoclonal antibodies in previously untreated chronic lymphocytic leukemia.
|
Clin Lymphoma Myeloma Leuk
|
2010
|
0.76
|
|
108
|
Chronic lymphocytic leukaemia.
|
Nat Rev Dis Prim
|
2017
|
0.76
|
|
109
|
Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR).
|
Br J Haematol
|
2009
|
0.75
|
|
110
|
The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experience.
|
Br J Haematol
|
2015
|
0.75
|
|
111
|
Genetics and molecular biology of chronic lymphocytic leukemia.
|
Curr Treat Options Oncol
|
2005
|
0.75
|
|
112
|
Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.
|
J Natl Compr Canc Netw
|
2017
|
0.75
|
|
113
|
Evolution of treatment strategies in chronic lymphocytic leukemia. Part 2 of a 3-Part series: Advances in the treatment of hematologic malignancies.
|
Clin Adv Hematol Oncol
|
2005
|
0.75
|